Niell H B
Van Vleet Cancer Center, University of Tennessee-Memphis, 3N Dunlap, Memphis, TN 38163, USA.
Curr Treat Options Oncol. 2001 Feb;2(1):71-6. doi: 10.1007/s11864-001-0018-4.
Small cell lung cancer is a rapidly proliferating, biologically aggressive form of lung cancer that has a short survival without treatment. Chemotherapy is the foundation of the therapeutic approach to patients with small cell lung cancer. Most patients present with extensive disease, and, although few patients are cured, significant improvement in survival is possible with modern chemotherapy. The role of radiation therapy in extensive disease is palliative, and surgery has little role in patient management. The standard chemotherapy regimen for patients with small cell lung cancer has become either cisplatin or carboplatin with etoposide. Second-line chemotherapy regimens are moderately effective in patients previously responding to initial chemotherapy. Newer chemotherapy agents show promise, but few randomized trials have been completed in extensive disease. Physicians should be encouraged to include their patients with extensive small cell lung cancer in the evolving clinical trials.
小细胞肺癌是一种增殖迅速、生物学行为具有侵袭性的肺癌，若不治疗生存期很短。化疗是小细胞肺癌患者治疗方法的基础。大多数患者就诊时已处于广泛期，虽然很少有患者能治愈，但现代化疗可显著提高生存率。放疗在广泛期疾病中的作用是姑息性的，手术在患者管理中作用不大。小细胞肺癌患者的标准化疗方案已变为顺铂或卡铂联合依托泊苷。二线化疗方案对先前对初始化疗有反应的患者有一定疗效。新型化疗药物显示出前景，但在广泛期疾病中完成的随机试验很少。应鼓励医生将广泛期小细胞肺癌患者纳入正在进行的临床试验。
